PSME3 and melanoma: To assess the impact of Ki affinity on immunogenicity of peptides in human, we took advantage of clinical trials in which cohorts of melanoma patients were vaccinated with formulations containing two different Melan-A/MART-1-specific peptides: the native low Ki affinity EAAGIGILTV peptide and the high Ki affinity ELAGIGILTV variant (13).